A patient on Haloperidol develops Neuroleptic Malignant Syndrome (rigidity, fever). What is the most appropri… - INI-CET EXAM -2025

INI-CET EXAM -2025

Pharmacology

Easy

Appeared in: INI-CET EXAM -2025

Explanation

The primary and most critical intervention for Neuroleptic Malignant Syndrome (NMS) is to immediately discontinue the causative antipsychotic medication.
Dantrolene, a direct-acting muscle relaxant, is administered to treat the severe muscle rigidity and hyperthermia characteristic of NMS.
Bromocriptine, a dopamine agonist, is given to help restore dopamine activity in the brain, addressing the core pathophysiological issue of dopamine blockade.
This combination of stopping the offending agent and administering specific antidotes is the standard, evidence-based treatment for this medical emergency.

Option B: NMS is primarily a disorder of dopamine blockade, not acetylcholine deficiency. Administering acetylcholine is not a recognized treatment and does not address the underlying cause.
Option C: Atropine is an anticholinergic agent. It is not used for NMS and can worsen symptoms like hyperthermia (by inhibiting sweating) and tachycardia.
Option D: This option is critically flawed because it advises continuing the antipsychotic. The causative drug must be stopped immediately. Continuing it would be life-threatening.

Visual 1: Flowchart: Management of Neuroleptic Malignant Syndrome - This visual would outline the steps from initial suspicion (fever, rigidity) to immediate actions (stop drug, supportive care) and specific treatments (dantrolene, bromocriptine).
Visual 2: Table: NMS vs. Serotonin Syndrome - A comparative table highlighting the key differences in causative drugs, clinical features (e.g., rigidity in NMS vs. clonus in SS), and treatment, which is a common point of confusion.

Clinical Relevance

Nursing practice connection: Use the key finding related to Management of Neuroleptic Malignant Syndrome (NMS) to guide bedside assessment, documentation, and the next nursing action.
Nurses must be able to rapidly identify the signs of NMS (fever, severe muscle rigidity, altered mental status, autonomic instability) as it is a medical emergency with a high mortality rate.
The nurse's primary responsibilities include holding the antipsychotic medication, notifying the physician immediately, and initiating supportive care measures like cooling blankets and IV hydration.
What if? If the patient presented with a less severe symptom like a tremor or a shuffling gait (drug-induced parkinsonism) instead of rigidity and fever, the intervention would be different. The nurse would report the symptoms, but the treatment might involve adding an anticholinergic agent (like benztropine) rather than stopping the antipsychotic and giving dantrolene.

How to Approach the Question

First, identify the key elements in the scenario: the drug (Haloperidol, a typical antipsychotic) and the classic symptoms (rigidity, fever).
Recognize that this combination points directly to the diagnosis of Neuroleptic Malignant Syndrome (NMS), a severe adverse reaction.
Recall the fundamental principles of managing a severe drug reaction: stop the offending agent and provide specific treatment/antidotes.
Evaluate the options based on this principle. Option A includes stopping the drug and giving the correct antidotes (dantrolene/bromocriptine).
Eliminate other options. Option D is incorrect because it continues the drug. Options B and C suggest incorrect pharmacological agents that do not address the pathophysiology of NMS.

Concept Tested & Keywords

Concept Tested: Management of Neuroleptic Malignant Syndrome (NMS)
Stem keywords: Haloperidol, Neuroleptic Malignant Syndrome, rigidity, fever
Lead-in keywords: most appropriate treatment
Clinical cues: Patient on an antipsychotic (Haloperidol) presenting with classic NMS symptoms (rigidity, fever) indicates a severe adverse drug reaction.

QFjCCEegx3vuFYhOKyNMKt